We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$396M 7.68%
8,379,642
-52,178
-0.6% -$2.91M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$123B
$303M 5.87%
1,273,089
-116,200
-8% -$26.7M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$282M 5.47%
3,259,474
-58,900
-2% -$5.76M
INCY icon
4
Incyte
INCY
$23.4B
$243M 4.72%
3,324,000
-193,000
-5% -$14.6M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$193M 3.75%
1,775,264
-89,519
-5% -$10.3M
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$159M 3.08%
5,037,890
+512,880
+11% +$27.1M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.36B
$139M 2.69%
3,905,444
-19,510
-0.5% -$902K
HALO icon
8
Halozyme
HALO
$9.23B
$138M 2.67%
7,663,956
-372,900
-5% -$7.08M
ARGX icon
9
argenx
ARGX
$53.8B
$128M 2.49%
974,504
+6,515
+0.7% +$954K
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$120M 2.32%
1,331,328
-57,600
-4% -$5.65M
MRNA icon
11
Moderna
MRNA
$24.5B
$118M 2.29%
3,950,181
-984,900
-20% -$22.7M
ISRG icon
12
Intuitive Surgical
ISRG
$122B
$109M 2.12%
661,113
+132,285
+25% +$24.2M
ABT icon
13
Abbott
ABT
$175B
$101M 1.97%
1,284,272
-41,148
-3% -$3.43M
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
$90.8M 1.76%
6,983,385
+41,000
+0.6% +$731K
MDT icon
15
Medtronic
MDT
$106B
$85.2M 1.65%
945,316
+96,986
+11% +$10.3M
ELV icon
16
Elevance Health
ELV
$80.9B
$83M 1.61%
365,603
+40,429
+12% +$11M
UNH icon
17
UnitedHealth
UNH
$387B
$78.9M 1.53%
316,208
+40,998
+15% +$11.3M
EXEL icon
18
Exelixis
EXEL
$14.1B
$68.5M 1.33%
3,975,400
+44,700
+1% +$818K
BMY icon
19
Bristol-Myers Squibb
BMY
$124B
$67.2M 1.3%
1,205,472
-883,770
-42% -$54M
HUM icon
20
Humana
HUM
$48B
$62.2M 1.21%
198,118
-29,329
-13% -$9.89M
NKTR icon
21
Nektar Therapeutics
NKTR
$2.31B
$62.2M 1.21%
232,314
+4,514
+2% +$1.4M
CI icon
22
Cigna
CI
$74.5B
$61.9M 1.2%
349,289
+30,143
+9% +$5.85M
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$61.5M 1.19%
1,311,713
+5,400
+0.4% +$346K
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$57.4M 1.11%
3,731,819
+1,365,819
+58% +$29.7M
BDX icon
25
Becton Dickinson
BDX
$43.6B
$56.8M 1.1%
253,241
-5,071
-2% -$1.25M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.